TMCnet News
Trelstar Drug Analysis Report 2018 - ResearchAndMarkets.comThe "Drug Analysis: Trelstar" drug pipelines has been added to ResearchAndMarkets.com's offering. Trelstar (triptorelin; Allergan) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as "flare" Persistent use of GnRH agonists over time causes downregulation of GnRH receptors in the pituitary gland, generating a significat reduction in LH and follicle-stimulating hormone secretion. This has the effect of complete shutdown of testosterone production in the testes, resulting in chemical castration. Key Topics Covered: List of Figures Figure 1: Trelstar sales for prostate cancer across the US and five major EU markets, by country, 2017-26 List of Tables Table 1: Trelstar sales for prostate cancer across the US and five major EU markets, by country ($m), 2017-26 For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/9mm6cv/trelstar_drug?w=4 View source version on businesswire.com: http://www.businesswire.com/news/home/20180219005521/en/ |
